Trevena, Inc. (NASDAQ:TRVN) traded down 5% on Wednesday . The stock traded as low as $2.61 and last traded at $2.65. 634,984 shares traded hands during trading, an increase of 24% from the average session volume of 511,169 shares. The stock had previously closed at $2.79.

Several equities research analysts have weighed in on the company. Zacks Investment Research cut Trevena from a “hold” rating to a “sell” rating in a research note on Wednesday, July 26th. Oppenheimer Holdings, Inc. set a $8.00 target price on Trevena and gave the stock a “buy” rating in a research note on Thursday, August 3rd. ValuEngine cut Trevena from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Cowen and Company restated a “buy” rating and set a $10.00 target price on shares of Trevena in a research note on Friday, August 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $10.56.

The stock’s market capitalization is $150.43 million. The company’s 50-day moving average price is $2.45 and its 200 day moving average price is $2.93.

Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). On average, equities analysts predict that Trevena, Inc. will post ($1.41) earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. California State Teachers Retirement System grew its position in Trevena by 0.5% in the second quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 500 shares in the last quarter. State Street Corp grew its position in Trevena by 8.3% in the second quarter. State Street Corp now owns 768,249 shares of the biopharmaceutical company’s stock worth $1,767,000 after acquiring an additional 58,895 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Trevena by 528.5% in the second quarter. Dimensional Fund Advisors LP now owns 711,615 shares of the biopharmaceutical company’s stock worth $1,637,000 after acquiring an additional 598,383 shares in the last quarter. Virtu KCG Holdings LLC grew its position in Trevena by 144.0% in the second quarter. Virtu KCG Holdings LLC now owns 58,660 shares of the biopharmaceutical company’s stock worth $135,000 after acquiring an additional 34,618 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Trevena by 15.0% in the second quarter. Vanguard Group Inc. now owns 1,822,103 shares of the biopharmaceutical company’s stock worth $4,191,000 after acquiring an additional 238,089 shares in the last quarter. Institutional investors own 60.13% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Trevena, Inc. (TRVN) Shares Down 5%” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/15/trevena-inc-trvn-shares-down-5.html.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.